Saturday, April 04, 2020 5:13:47 AM
“We are excited to have Aileen join us and strengthen our leadership team’s core capabilities, as her strategic track record and vast industry network will add tremendous value to the organization”, commented Harel Gadot, CEO, President and Chairman. “Her proven experience in merger and acquisition transactions as well as the formation and execution of strategic collaborations across the industry, will greatly enhance the Company’s ability to achieve its strategic growth objectives.”
During her almost 30 years at Johnson & Johnson, Ms. Stockburger held several business development and finance roles in Medical Devices, Corporate and Consumer. She served as Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group’s merger and acquisition activities. While in that role, she played leading and significant roles in over $70 billion worth of transactions, including: Johnson and Johnson’s acquisition of Synthes, as well as Pfizer Consumer HealthCare, Aveeno, BabyCenter, OraPharma, DePuy, DePuy Mitek, Kodak Clinical Diagnostics and Neutrogena. Before joining Johnson & Johnson, Aileen spent three years at PriceWaterhouse Coopers, where she earned her CPA certification. She received her BS and MBA from the Wharton School, University of Pennsylvania
“Throughout my career I have sought out opportunities that allow me to use my specific skills to help effect meaningful change and impact to the healthcare market,” commented Ms. Stockburger. “I have watched Microbot Medical the past few years, albeit from a distance, and my enthusiasm to join the Board at this specific time is due to its progress developing highly advanced and revolutionary robotic systems that will transform the future of healthcare. I believe that my expertise, combined with Microbot’s assets and ambition, will allow us to address new and emerging growth markets.”
Recent MBOT News
- Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™ • GlobeNewswire Inc. • 04/29/2024 12:30:00 PM
- Microbot Medical Shares Status Following Recent Geopolitical Events • GlobeNewswire Inc. • 04/15/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 11:41:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 11:41:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 11:41:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 11:41:08 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/20/2024 09:35:10 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:49:35 PM
- Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US • GlobeNewswire Inc. • 02/05/2024 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/30/2024 09:30:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 12:20:27 PM
- Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters • GlobeNewswire Inc. • 01/30/2024 12:20:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/26/2024 05:15:33 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/22/2024 10:20:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 12:20:26 PM
- Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study • GlobeNewswire Inc. • 01/18/2024 12:20:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 09:20:41 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/12/2024 09:16:06 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/02/2024 10:00:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 09:55:51 PM
- Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 12/29/2023 01:00:00 PM
- Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met • GlobeNewswire Inc. • 12/28/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 01:15:27 PM
- Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic • GlobeNewswire Inc. • 12/14/2023 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 01:00:28 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM